Free Trial
NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

Artelo Biosciences logo
$10.80 -0.24 (-2.13%)
Closing price 07/3/2025 03:49 PM Eastern
Extended Trading
$10.80 0.00 (0.00%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Artelo Biosciences Stock (NASDAQ:ARTL)

Key Stats

Today's Range
$9.84
$11.01
50-Day Range
$5.43
$13.27
52-Week Range
$4.92
$25.58
Volume
91,305 shs
Average Volume
136,216 shs
Market Capitalization
$5.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.00
Consensus Rating
Buy

Company Overview

Artelo Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
61st Percentile Overall Score

ARTL MarketRank™: 

Artelo Biosciences scored higher than 61% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artelo Biosciences has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Artelo Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Artelo Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Artelo Biosciences are expected to grow in the coming year, from ($2.62) to ($1.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artelo Biosciences is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artelo Biosciences is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artelo Biosciences has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Artelo Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.18% of the float of Artelo Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Artelo Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Artelo Biosciences has recently decreased by 93.88%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Artelo Biosciences does not currently pay a dividend.

  • Dividend Growth

    Artelo Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.18% of the float of Artelo Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Artelo Biosciences has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Artelo Biosciences has recently decreased by 93.88%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Artelo Biosciences has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Artelo Biosciences this week, compared to 0 articles on an average week.
  • Search Interest

    3 people have searched for ARTL on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.83% of the stock of Artelo Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 0.87% of the stock of Artelo Biosciences is held by institutions.

  • Read more about Artelo Biosciences' insider trading history.
Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ARTL Stock News Headlines

ARTL - Artelo Biosciences Inc Sustainability - Morningstar
Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Headlines

ARTL Stock Analysis - Frequently Asked Questions

Artelo Biosciences' stock was trading at $6.36 at the beginning of 2025. Since then, ARTL stock has increased by 69.7% and is now trading at $10.7950.

Artelo Biosciences, Inc. (NASDAQ:ARTL) released its earnings results on Tuesday, May, 13th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $3.54.

Artelo Biosciences's stock reverse split on Friday, June 13th 2025.The 1-6 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/13/2025
Today
7/04/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTL
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$33.00
High Stock Price Target
$36.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+205.7%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.83 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$5.31 per share
Price / Book
2.03

Miscellaneous

Free Float
542,000
Market Cap
$5.94 million
Optionable
Not Optionable
Beta
1.34
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:ARTL) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners